First let's define an "ideal universal cancer marker".
The ideal marker is a molecule that's present in all cancer cells of all tissue types -- none of the present markers can do that; and RECAF is the only one discovered to date that comes very close to that ideal. Cancer markers are molecules found in human cells that identify certain cellular characteristics. By notating whether markers are present or not, scientists are able to determine whether a cell is normal, benign, or cancerous. The best cancer markers to date (AFP, CEA, PSA, and Ca125) are limited by their ability to identify cancer only in certain organs. RECAF works across the board, showing very high sensitivity and specificity in ALL cancers. Having the ability to find the marker in the bloodstream is a tremendous advantage over doing a biopsy. It's simple, it's efficient, and it can be applied to some of the most common types of cancer for which there are no other useful markers.
A further advantage of RECAF is that it's found in not only the tissue of cancer patients so biopsies can be examined, but also in the bloodstream so that a simple blood test can be used to detect cancer.
WE HAVE IT ALL!!!!
1) You have NO IDEA what is happening w/not only Abbott or Inverness, but also Bhlokin or Goshen. Did you know that Goshen was working on a rapid saliva test before they published their preliminary results?
Do you know what they are working on right now? I don't. I admit it.
The collaboration with Biocurex and the Center for Cancer Care is LONG TERM and will consist of THREE PHASES: The first one will CONTINUE AND EXPAND the applications of serum and biopsy tests using RECAF(tm). The second phase will focus on IMAGING applications using RECAF(tm) to detect the location of cancerous tumors in the body. The third phase includes CLINICAL TRIALS in which RECAF(tm) will be used as a way to specifically deliver therapeutic agents to destroy the cancer cells with minimal damage to normal tissues. The third phase is contingent to the previous development of animal and culture models demonstrating the benefits of RECAF for targeting cancer cells.
Dr. Douglas Schwartzentruber, medical director of Goshen Health System's Center for Cancer Care stated, "In many ways this is an ideal partnership that brings together the strengths of our institutions, both in the basic sciences and the clinical arena."
Dr. Douglas Schwartzentruber is a surgical oncologist who completed a fellowship in Immunotherapy at the National Cancer Institute, Bethesda, Maryland where he subsequently worked for 13 years as a senior investigator. Dr. Schwartzentruber's research on the role of vaccines in the treatment of malignant melanoma, has gained both national and international attention. He serves on the editorial board for the American Journal of Oncology Review and the Journal of Translational Medicine.
An ideal cancer marker is a molecule present in all cancer cells but not in normal or benign tumor cells. RECAF(tm) could become the one cancer marker suitable to detect all cancer types. The potential benefit RECAF(tm) offers to patients is a superior diagnostic tool and a new way to deliver targeted therapy. RECAF IS UNIQUE! IT IS THE DEFINITION OF AN IDEAL CANCER MARKER.
2) Most recently in Feb 2009 in Barcelona, Spain Dr Moro presented in front of 400 scientists. Dr. Moro's presentation was very well received and as a
result, two top clinical chemistry groups expressed an interest in developing collaborations with BioCurex to independently validate the usefulness of RECAF
in the clinical environment as well as to further advance the research on this marker. The directors of these teams are members of the European Group on Tumor Markers, an institution heavily involved in creating the recommendations for the
use of cancer markers in the European Union, which are also followed by other countries. These two scientists have published over 250 scientific papers on the
use of cancer markers.
(READ ON, THIS IS GREAT STUFF!!!!!!!!!!)
Dr. Moro stated: "We are very pleased with the interest elicited by our results. These collaborations translate into several important elements for BioCurex:
* They will work completely independently from BioCurex and therefore the data thus produced can be used for regulatory purposes not only in Europe, but also in America.
* They will perform all the work at their expense with the exception of the cost of the tests, which BioCurex will initially provide
free of cost.
* The two groups evaluate and publish results for diagnostic products marketed by large diagnostic companies, including Abbott and Roche, and therefore their opinions and recommendations are important for companies working in the field.
* Finally, since these scientists are leaders in the field; their independent validation of our results may prompt of other scientists to work with RECAF, which besides the obvious scientific impact could also become a source of revenue.
***********THAT IS 2, WANT MORE?*******************
We can detect ALL types of cancer multiple ways via immunoassays (The specificity of the antibody-antigen interaction makes immunoassays an ideal diagnostic and research tool.....The higher the affinity of the antibody for the antigen, the more stable the interaction and the easier it is to detect in immunoassays).
1)Radioimmunoassay (RIA)----The basic principle of RIAs is that antigenspecific antibodies are allowed to bind to a known quantity of radioactive antigen. The bound radioactivity is then measured.
2)Enzyme immunoassays (ELISA)----There are essentially two main types of ELISA: (1) sandwich ELISA and (2) competitive ELISA. Sandwich ELISA is used for detection of larger antigens containing at least two epitopes. A micro-plate is coated with antibody specific for one epitope of the antigen of interest. Then the sample containing the antigen is incubated on the coated plate. Finally, an enzymeconjugated antibody specific for a second epitope on the antigen of interest is added, the presence of enzyme conjugate bound to the plate is detected using an appropriate substrate, the resulting signal is measured with a micro-plate reader.
3)Chemiluminescent immunoassays----Chemiluminescence refers to the emission of light caused by a chemical reaction. Measurement of light from a chemical reaction is highly useful because the concentration of an unknown can be inferred from the rate at which light is emitted. The rate of light output is directly related to the amount of light emitted and proportional to the concentration of the luminescent material present. Chemiluminescent assays have become more widely used in recent years because of their excellent sensitivity and the reagents are stable and nontoxic.
Bottomline, Goldseeker it is time for a vacation. See ya!
